{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T00:41:04Z","timestamp":1702082464410},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T00:00:00Z","timestamp":1701993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T00:00:00Z","timestamp":1701993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"BAXALTA US Inc, now part of TAKEDA","award":["H16-35563"],"award-info":[{"award-number":["H16-35563"]}]},{"DOI":"10.13039\/501100001700","name":"The Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"crossref","award":["26461593 and 21K07804"],"award-info":[{"award-number":["26461593 and 21K07804"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Thrombosis J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Von Willebrand factor (VWF) and factor VIII (FVIII) complex play a pivotal role in hemostasis. A deficiency or defect of VWF causes von Willebrand disease (VWD). Recombinant (r)VWF product has proved to be effective for hemostatic treatment of VWD, but limited information is available on their role in moderating thrombus formation under flow condition. We aimed to assess thrombus formation in the presence of rVWF combined with rFVIII or pegylated-extended half-life rFVIII (peg-EHL-rFVIII) in VWD whole blood under high shear flow.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Perfusion chamber experiments under high shear (2,500\u00a0s<jats:sup>\u2212\u20091<\/jats:sup>) combined with immunostaining were performed using patient\u2019s whole blood with type 1 VWD, mixed with rVWF (Vonvendi<jats:sup>\u00ae<\/jats:sup>; 1.6 IU\/mL), rFVIII or peg-EHL-rFVIII (Advate<jats:sup>\u00ae<\/jats:sup> or Adynovate<jats:sup>\u00ae<\/jats:sup>; 1.0 IU\/mL), or both. Similar experiments were also conducted with clinical medical devices (T-TAS<jats:sup>\u00ae<\/jats:sup>).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The addition of rFVIII did not augment thrombus formation assessed by surface coverage (SC) and thrombus height (TH), whereas rVWF enhanced these parameters (SC 19.1\u2009\u00b1\u20091.1% vs. 30.1\u2009\u00b1\u20094.1%, TH 2.2\u2009\u00b1\u20090.14\u00a0\u03bcm vs. 3.6\u2009\u00b1\u20090.40\u00a0\u03bcm, respectively). The co-presence of rVWF\/rFVIII was comparable to plasma-derived VWF\/FVIII (Confact<jats:sup>\u00ae<\/jats:sup>, VWF:FVIII ratio\u2009=\u20091.6:1.0) for increasing thrombogenicity in SC (32.5\u2009\u00b1\u20094.3% vs. 38.7\u2009\u00b1\u20095.5%) and in TH (5.0\u2009\u00b1\u20090.60\u00a0\u03bcm vs. 5.5\u2009\u00b1\u20090.64\u00a0\u03bcm), respectively. The pre-incubation time with rVWF and rFVIII appeared to have a little effect on the size of thrombus. Peg-EHL-rFVIII mediated thrombus formation to similar extent as rFVIII in the co-presence of rVWF. Similar results were obtained even with T-TAS. Immunostaining demonstrated that rFVIII and peg-EHL-rFVIII were similarly co-localized with rVWF in formed thrombi, indicating that pegylation did not interfere with molecular complexes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The effects of high-level rVWF and peg-EHL-rFVIII on thrombus formation were comparable to conventional therapeutic products in a patient\u2019s whole blood with VWD under high shear flow.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12959-023-00569-1","type":"journal-article","created":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T17:02:33Z","timestamp":1702054953000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hemostatic potential of recombinant von Willebrand factor and standard or pegylated extended half-life recombinant factor VIII on thrombus formation under high shear flow"],"prefix":"10.1186","volume":"21","author":[{"given":"Hiroaki","family":"Yaoi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuaki","family":"Shida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Ogiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiji","family":"Nogami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,8]]},"reference":[{"key":"569_CR1","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s00109-010-0691-5","volume":"89","author":"D Stegner","year":"2011","unstructured":"Stegner D, Nieswandt B. Platelet receptor signaling in thrombus formation. J Mol Med. 2011;89:109\u201321.","journal-title":"J Mol Med"},{"key":"569_CR2","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1146\/annurev.biochem.67.1.395","volume":"67","author":"JE Sadler","year":"1998","unstructured":"Sadler JE. Biochemistry and genetics of Von Willebrand factor. Annu Rev Biochem. 1998;67:395\u2013424.","journal-title":"Annu Rev Biochem"},{"key":"569_CR3","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1182\/blood.V87.6.2292.bloodjournal8762292","volume":"87","author":"SJ Koppelman","year":"1996","unstructured":"Koppelman SJ, van Hoeij M, Vink T, Lankhof H, Schiphorst ME, Vlot A, et al. Requirements of Von Willebrand factor to protect factor VIII from inactivation by activated protein C. Blood. 1996;87:2292\u2013300.","journal-title":"Blood"},{"key":"569_CR4","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1111\/j.1538-7836.2006.02146.x","volume":"4","author":"JE Sadler","year":"2006","unstructured":"Sadler JE, Budde U, Eikenboom JCJ, Favaloro EJ, Hill FG, Holmberg L, et al. Update on the pathophysiology and classification of Von Willebrand Disease: a report of the Subcommittee on Von Willebrand factor. J Thromb Haemost. 2006;4:2103\u201314.","journal-title":"J Thromb Haemost"},{"key":"569_CR5","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1055\/s-0033-1354420","volume":"39","author":"G Di Minno","year":"2013","unstructured":"Di Minno G, Canaro M, Ironside JW, Navarro D, Perno CF, Tiede A, et al. Pathogen safety of long-term treatments for bleeding disorders: (Un)predictable risks and evolving threats. Semin Thromb Hemost. 2013;39:779\u201393.","journal-title":"Semin Thromb Hemost"},{"key":"569_CR6","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1182\/blood.V79.12.3130.bloodjournal79123130","volume":"79","author":"PM Mannucci","year":"1992","unstructured":"Mannucci PM, Tenconi PM, Castaman G, Rodeghiero F. Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand Disease: a cross-over randomized trial. Blood. 1992;79:3130\u20137.","journal-title":"Blood"},{"key":"569_CR7","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1182\/blood.V83.10.3018.3018","volume":"83","author":"PM Mannuccio","year":"1994","unstructured":"Mannuccio PM, Lattuada A, Ruggeri ZM. Proteolysis of Von Willebrand factor in therapeutic plasma concentrates. Blood. 1994;83:3018\u201327.","journal-title":"Blood"},{"key":"569_CR8","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1182\/blood-2015-02-629873","volume":"126","author":"JC Gill","year":"2015","unstructured":"Gill JC, Castaman G, Windyga J, Kouides P, Ragni M, Leebeek FWG, et al. Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand Disease. Blood. 2015;126:2038\u201346.","journal-title":"Blood"},{"key":"569_CR9","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1182\/blood-2013-01-479527","volume":"122","author":"PM Mannucci","year":"2013","unstructured":"Mannucci PM, Kempton C, Millar C, Romond E, Shapiro A, Birschmann I, et al. Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial. Blood. 2013;122:648\u201357.","journal-title":"Blood"},{"key":"569_CR10","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1182\/blood-2015-03-630897","volume":"126","author":"BA Konkle","year":"2015","unstructured":"Konkle BA, Stasyshyn O, Chowdary P, Bevan DH, Mant T, Shima M, et al. Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. Blood. 2015;126:1078\u201385.","journal-title":"Blood"},{"key":"569_CR11","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1055\/s-0038-1651588","volume":"69","author":"M Shima","year":"1993","unstructured":"Shima M, Scandella D, Yoshioka A, Nakai H, Tanaka I, Kamisue S, et al. A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to Von Willebrand factor and to phosphatidylserine. Thromb Haemost. 1993;69:240\u20136.","journal-title":"Thromb Haemost"},{"key":"569_CR12","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1046\/j.1365-2141.1999.01673.x","volume":"107","author":"K Nogami","year":"1999","unstructured":"Nogami K, Shima M, Nakai H, Tanaka I, Suzuki H, Morichika S, et al. Identification of a factor VIII peptide, residues 2315\u20132330, which neutralizes human factor VIII C2 inhibitor alloantibodies: requirement of Cys2326 and Glu2327 for maximum effect. Br J Haematol. 1999;107:196\u2013203.","journal-title":"Br J Haematol"},{"key":"569_CR13","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1182\/blood-2013-09-521484","volume":"124","author":"Y Shida","year":"2014","unstructured":"Shida Y, Rydz N, Stegner D, Brown C, Mewburn J, Sponagle K, et al. Analysis of the role of Von Willebrand factor, platelet glycoprotein VI-, and \u03b12\u03b21-mediated collagen binding in thrombus formation. Blood. 2014;124:1799\u2013807.","journal-title":"Blood"},{"key":"569_CR14","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1055\/s-0040-1716542","volume":"121","author":"H Yaoi","year":"2021","unstructured":"Yaoi H, Shida Y, Kitazawa T, Shima M, Nogami K. Emicizumab augments thrombus formation in whole blood from patients with hemophilia A under high shear flow conditions. Thromb Haemost. 2021;121:279\u201386.","journal-title":"Thromb Haemost"},{"key":"569_CR15","doi-asserted-by":"publisher","first-page":"e194","DOI":"10.1111\/hae.14272","volume":"27","author":"H Yaoi","year":"2021","unstructured":"Yaoi H, Shida Y, Kitazawa T, Shima M, Nogami K. Emicizumab improves thrombus formation of type 2A Von Willebrand Disease under high shear condition. Haemophilia. 2021;27:e194\u2013e203.","journal-title":"Haemophilia"},{"key":"569_CR16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.thromres.2020.11.026","volume":"198","author":"H Yaoi","year":"2021","unstructured":"Yaoi H, Shida Y, Kitazawa T, Shima M, Nogami K. Activated factor VIII-mimicking effect by emicizumab on thrombus formation in type 2\u00a0N von Willebrand Disease under high shear flow conditions. Thromb Res. 2021;198:7\u201316.","journal-title":"Thromb Res"},{"key":"569_CR17","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1111\/j.1538-7836.2011.04464.x","volume":"9","author":"K Hosokawa","year":"2011","unstructured":"Hosokawa K, Ohnishi T, Kondo T, Fukasawa M, Koide T, Maruyama I, et al. A novel automated microchip flow-chamber system to quantitatively evaluate thrombus formation and antithrombotic agents under blood flow conditions. J Thromb Haemost. 2011;9:2029\u201337.","journal-title":"J Thromb Haemost"},{"key":"569_CR18","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1111\/jth.13273","volume":"14","author":"K Nogami","year":"2016","unstructured":"Nogami K, Ogiwara K, Yada K, Shida Y, Takeyama M, Yaoi H, et al. Assessing the clinical severity of type 1 von Willebrand Disease patients with a microchip flow-chamber system. J Thromb Haemost. 2016;14:667\u201374.","journal-title":"J Thromb Haemost"},{"key":"569_CR19","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1042\/bj2000161","volume":"200","author":"LO Andersson","year":"1981","unstructured":"Andersson LO, Brown JE. Interaction of factor VIII-von willebrand factor with phospholipid vesicles. Biochem J. 1981;200:161\u20137.","journal-title":"Biochem J"},{"key":"569_CR20","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.1182\/blood-2013-06-498303","volume":"122","author":"D Lillicrap","year":"2013","unstructured":"Lillicrap D. Von Willebrand Disease: advances in pathogenetic understanding, diagnosis, and therapy. Blood. 2013;122:3735\u201340.","journal-title":"Blood"},{"key":"569_CR21","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1182\/blood-2007-09-110700","volume":"111","author":"Y Shida","year":"2008","unstructured":"Shida Y, Nishio K, Sugimoto M, Mizuno T, Hamada M, Kato S, et al. Functional imaging of shear-dependent activity of ADAMTS13 in regulating mural thrombus growth under whole blood flow conditions. Blood. 2008;111:1295\u20138.","journal-title":"Blood"}],"container-title":["Thrombosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-023-00569-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12959-023-00569-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-023-00569-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T17:04:35Z","timestamp":1702055075000},"score":1,"resource":{"primary":{"URL":"https:\/\/thrombosisjournal.biomedcentral.com\/articles\/10.1186\/s12959-023-00569-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,8]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["569"],"URL":"https:\/\/doi.org\/10.1186\/s12959-023-00569-1","relation":{},"ISSN":["1477-9560"],"issn-type":[{"value":"1477-9560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,8]]},"assertion":[{"value":"22 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Medical Research Ethics Committee of Nara Medical University, and blood samples were collected after informed consent following the University ethical guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HY, YS, KO, and KN have received research grants from Baxalta and Shire. KN has received research grants from Takeda and KM Biologics. KN has received honoraria from Shire, Takeda, KM Biologics, and Chugai.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"122"}}